1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bioventix Plc

Bioventix Plc

23.60
EUR
0.00
(0.00%)
106.63MMarket Cap
Oct 26Next Earn
Bioventix Plc
GETTEX:51B
(Gettex)

Recent

price

23.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
GBP
0.39
0.47
0.54
0.7
0.86
1.09
1.42
1.7
1.81
2
2.1
2.25
2.46
2.61
2.51
- -
Revenue per Share
0.18
0.25
0.3
0.36
0.51
0.69
0.96
1.1
1.14
1.39
1.29
1.47
1.61
1.55
1.45
- -
Basic EPS, GAAP
0.15
0.24
0.26
0.35
0.4
0.62
0.77
1.13
1.13
1.42
1.17
1.45
1.49
1.6
1.34
- -
Free Cash Flow per Basic Share
0.1
0.11
0.13
0.18
0.25
0.38
0.66
0.96
1.21
1.26
1.48
1.52
1.62
1.58
1.57
- -
Dividend per Share
0.53
0.66
0.83
1.04
1.3
1.62
1.97
2.14
2.11
2.4
2.27
2.27
2.31
2.3
2.21
2.11
Book Value per Share
0.52
0.66
0.83
1.04
1.3
1.62
1.97
2.14
2.11
2.4
2.27
2.27
2.31
2.3
2.21
2.11
Tangible Book Value per Share
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
Basic Weighted Avg Shares
2
2
3
4
4
6
7
9
9
10
11
12
13
14
13
- -
Sales/Revenue/Turnover
54.7
62.7
66.86
67.08
71.48
74.85
78.81
78.9
75.68
77.39
76.68
78.34
78.57
78.1
76.8
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
2
2
3
3
5
6
6
7
7
8
8
8
8
- -
Net Income, GAAP
18.38
17.86
16.47
18.61
17.65
17.17
14.72
17.52
15.85
12.43
17.08
17.29
17.39
23.64
24.88
- -
Effective Tax Rate (%)
44.82
51.9
56.22
51.35
59.02
63.34
67.93
64.71
63.1
69.84
61.58
65.48
65.33
59.51
57.83
- -
Profit Margin (%)
2
3
4
5
6
8
10
10
10
11
10
11
11
11
11
10
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
3
4
5
7
8
10
11
11
13
12
12
12
12
12
11
Total Equity
- -
39.09
38.42
35.63
40.97
45.22
51.88
51.75
50.83
59.25
53.09
61.48
65.26
62.09
58.11
- -
Return on Invested Capital (%)
- -
41.13
40.33
38.46
43.3
47.25
53.64
53.54
53.68
61.7
55.31
64.92
70.1
67.29
64.4
- -
Return on Capital (%)
- -
41.12
40.33
38.46
43.27
47.25
53.64
53.54
53.68
61.7
55.31
64.92
70.1
67.29
64.4
- -
Return on Common Equity (%)

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
163
141
93

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
12
12
12
Cash, Cash Equivalents & STI
5
5
5
Accounts Receivable, Net
6
1
6
Inventories
1
1
1
Total Current Liabilities
2
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.3%
-1.56%
-3.76%
Free Cash Flow
15.54%
0.25%
-15.8%
Net Income, GAAP
12.59%
1.39%
-6.33%
Sales/Revenue/Turnover
12.17%
5.02%
-3.61%
Total Cash Common Dividend
22.72%
4.99%
-0.63%

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
14
2025
- -
- -
13
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.55
2025
- -
- -
1.45
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.58
2025
- -
- -
1.57
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Bioventix PLC Bioventix plc develops and supplies high-affinity sheep monoclonal antibodies for clinical diagnostics and immunoassay applications; offers a portfolio of over 20 sheep monoclonal antibodies (SMAs) targeting low-concentration analytes for blood tests detecting heart disease, cancer, fertility issues, thyroid function, drug abuse, infectious diseases and vitamin D levels; provides Pyrene (HOP-G) ELISA kits and lateral flow kits for monitoring industrial pollutant exposure in urine samples. The company, founded in 2003 and headquartered at 7 Romans Business Park, Farnham, Surrey, UK, focuses on clinical diagnostics and drugs-of-abuse testing, supplying products and services to multinational in vitro diagnostic firms worldwide, with significant revenue from royalties, physical antibody sales and R&D contracts primarily in USD, Euros and Asian currencies. Bioventix PLC pursues ongoing collaborations, including with the University of Gothenburg on Alzheimer's disease biomarkers such as brain-derived tau antibodies generating initial R&D revenue, and advances its industrial biomonitoring platform with new point-of-exposure lateral flow testing; reports steady organic growth evidenced by 6% revenue increase and 5% profit rise for the year ended 30 June 2025, alongside new troponin assays for coronary assessments and rising demand in China.